Elevate Capital Advisors LLC Purchases 2,409 Shares of AbbVie Inc. $ABBV

Elevate Capital Advisors LLC lifted its position in shares of AbbVie Inc. (NYSE:ABBV) by 33.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 9,617 shares of the company’s stock after purchasing an additional 2,409 shares during the period. AbbVie accounts for about 1.6% of Elevate Capital Advisors LLC’s holdings, making the stock its 29th biggest position. Elevate Capital Advisors LLC’s holdings in AbbVie were worth $2,227,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Ellenbecker Investment Group increased its position in shares of AbbVie by 0.8% during the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock valued at $1,235,000 after acquiring an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA grew its position in AbbVie by 0.3% during the third quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock valued at $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC increased its holdings in AbbVie by 0.3% during the third quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC raised its position in AbbVie by 2.2% in the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock worth $484,000 after acquiring an additional 45 shares during the period. Finally, Willner & Heller LLC boosted its stake in AbbVie by 0.6% in the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after acquiring an additional 46 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

AbbVie Trading Up 0.7%

AbbVie stock opened at $222.21 on Thursday. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The firm has a market capitalization of $392.72 billion, a PE ratio of 168.34, a price-to-earnings-growth ratio of 0.92 and a beta of 0.36. The firm’s 50 day simple moving average is $226.94 and its 200 day simple moving average is $216.08.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $3.00 EPS. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date is Friday, January 16th. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. AbbVie’s dividend payout ratio is 496.97%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie says it will build out its presence in the fast-growing obesity-treatment market, leveraging a weight‑loss drug it licensed from Danish biotech Gubra — opens a new growth avenue beyond core franchises. AbbVie plans to build out its presence in obesity market
• Positive Sentiment: AbbVie reached a three‑year drug‑pricing pact with the U.S. administration that includes a $100 billion U.S. R&D/investment pledge and exemptions from certain tariffs — reduces policy/tariff risk and signals regulatory cooperation. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to a ~$5.6B licensing partnership with RemeGen to access a PD‑1xVEGF bispecific oncology candidate — expands oncology pipeline and potential future revenue streams. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: AbbVie is acquiring a drug‑delivery system and an Arizona manufacturing facility from West Pharma and is spending on U.S. manufacturing capacity (including a reported $175M plant) — strengthens supply chain and supports on‑shore production. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Management’s full transcript from the J.P. Morgan Healthcare Conference provides detail on strategy and pipeline positioning — useful for modeling but no single market‑moving surprise in the transcript itself. AbbVie Inc. (ABBV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Several analyst/market pieces highlight bullish sentiment and long‑term value arguments for ABBV; these can support momentum but reflect secondary commentary rather than new company facts. Wall Street Bulls Look Optimistic About AbbVie (ABBV): Should You Buy?
• Neutral Sentiment: AbbVie joined industry calls for the FDA to update post‑approval change rules — a regulatory engagement that could benefit manufacturers broadly if successful but is a longer‑term policy push. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Negative Sentiment: The U.S. drug‑pricing agreement includes commitments to lower some U.S. prices and Medicaid impacts — this could weigh on near‑term revenue/margins for affected products even as tariff/other risks are reduced. ABBV Inks Drug Pricing Deal With Trump, Joins PD-1xVEGF Bandwagon

Analyst Ratings Changes

ABBV has been the subject of several research analyst reports. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a report on Tuesday, November 4th. UBS Group restated a “neutral” rating on shares of AbbVie in a research note on Tuesday. Guggenheim increased their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Finally, Morgan Stanley boosted their price objective on AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research note on Friday, December 12th. Three analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $246.89.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.